{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:08Z","timestamp":1791644588256,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010686","name":"H2020 European Institute of Innovation and Technology","doi-asserted-by":"publisher","award":["731377"],"award-info":[{"award-number":["731377"]}],"id":[{"id":"10.13039\/100010686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction and hypothesis<\/jats:title>\n                <jats:p>The purpose was to investigate the safety and feasibility of transurethral injections of autologous muscle precursor cells (MPCs) into the external urinary sphincter (EUS) to treat stress urinary incontinence (SUI) in female patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Prospective and randomised phase I clinical trial. Standardised 1-h pad test, International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF), urodynamic study, and MRI of the pelvis were performed at baseline and 6 months after treatment. MPCs gained through open muscle biopsy were transported to a GMP facility for processing and cell expansion. The final product was injected into the EUS via a transurethral ultrasound-guided route. Primary outcomes were defined as any adverse events (AEs) during follow-up. Secondary outcomes were functional, questionnaire, and radiological results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ten female patients with SUI grades I\u2013II were included in the study and 9 received treatment. Out of 8 AEs, 3 (37.5%) were potentially related to treatment and treated conservatively: 1 urinary tract infection healed with antibiotics treatment, 1 dysuria and 1 discomfort at biopsy site. Functional urethral length under stress was 25 mm at baseline compared with 30 mm at 6 months\u2019 follow-up (<jats:italic>p<\/jats:italic>=0.009). ICIQ-UI-SF scores improved from 7 points at baseline to 4 points at follow-up (<jats:italic>p<\/jats:italic>=0.035). MRI of the pelvis revealed no evidence of tumour or necrosis, whereas the diameter of the EUS muscle increased from 1.8 mm at baseline to 1.9 mm at follow-up (<jats:italic>p<\/jats:italic>=0.009).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Transurethral injections of autologous MPCs into the EUS for treatment of SUI in female patients can be regarded as safe and feasible. Only a minimal number of expected and easily treatable AEs were documented.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00192-023-05514-4","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T13:03:03Z","timestamp":1681304583000},"page":"2197-2206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Transurethral injection of autologous muscle precursor cells for treatment of female stress urinary incontinence: a prospective phase I clinical trial"],"prefix":"10.1007","volume":"34","author":[{"given":"Florian A.","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny A.","family":"Prange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Kozomara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Betschart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa A.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Steinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Hunziker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Veit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Landsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"H\u00f6tker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Boss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deana","family":"Mohr-Haralampieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"issue":"7","key":"5514_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132\u20138.","journal-title":"BJU Int"},{"issue":"9504","key":"5514_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0140-6736(06)67925-7","volume":"367","author":"P Norton","year":"2006","unstructured":"Norton P, Brubaker L. Urinary incontinence in women. Lancet. 2006;367(9504):57\u201367.","journal-title":"Lancet"},{"issue":"16","key":"5514_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1001\/jama.2017.12137","volume":"318","author":"ES Lukacz","year":"2017","unstructured":"Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592\u2013604.","journal-title":"JAMA"},{"issue":"3","key":"5514_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1464-410X.2003.04609.x","volume":"93","author":"S Hunskaar","year":"2004","unstructured":"Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004;93(3):324\u201330.","journal-title":"BJU Int"},{"issue":"6","key":"5514_CR5","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/nau.23121","volume":"36","author":"JM Linde","year":"2017","unstructured":"Linde JM, Nijman RJM, Trzpis M, Broens PMA. Urinary incontinence in the Netherlands: prevalence and associated risk factors in adults. Neurourol Urodyn. 2017;36(6):1519\u201328.","journal-title":"Neurourol Urodyn"},{"key":"5514_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejogrb.2014.02.008","volume":"176","author":"MR Asoglu","year":"2014","unstructured":"Asoglu MR, Selcuk S, Cam C, Cogendez E, Karateke A. Effects of urinary incontinence subtypes on women's quality of life (including sexual life) and psychosocial state. Eur J Obstet Gynecol Reprod Biol. 2014;176:187\u201390.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"5514_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/ijerph14060577","volume":"14","author":"M Ptak","year":"2017","unstructured":"Ptak M, Brodowska A, Ciecwiez S, Rotter I. Quality of life in women with stage 1 stress urinary incontinence after application of conservative treatment\u2014a randomized trial. Int J Environ Res Public Health. 2017;14(6):577","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"5514_CR8","first-page":"398","volume":"98","author":"L Wilson","year":"2001","unstructured":"Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98(3):398\u2013406.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"5514_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.urology.2003.10.037","volume":"63","author":"TW Hu","year":"2004","unstructured":"Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63(3):461\u20135.","journal-title":"Urology"},{"issue":"2","key":"5514_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ajog.2005.07.051","volume":"194","author":"KN Danforth","year":"2006","unstructured":"Danforth KN, Townsend MK, Lifford K, Curhan GC, Resnick NM, Grodstein F. Risk factors for urinary incontinence among middle-aged women. Am J Obstet Gynecol. 2006;194(2):339\u201345.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"5514_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5213\/inj.2012.16.3.102","volume":"16","author":"J Jung","year":"2012","unstructured":"Jung J, Ahn HK, Huh Y. Clinical and functional anatomy of the urethral sphincter. Int Neurourol J. 2012;16(3):102\u20136.","journal-title":"Int Neurourol J"},{"issue":"4","key":"5514_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.juro.2017.06.061","volume":"198","author":"KC Kobashi","year":"2017","unstructured":"Kobashi KC, Albo ME, Dmochowski RR, et al. Surgical treatment of female stress urinary incontinence: AUA\/SUFU guideline. J Urol. 2017;198(4):875\u201383.","journal-title":"J Urol"},{"issue":"4","key":"5514_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","volume":"73","author":"AK Nambiar","year":"2018","unstructured":"Nambiar AK, Bosch R, Cruz F, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018;73(4):596\u2013609.","journal-title":"Eur Urol"},{"issue":"2","key":"5514_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijgo.2011.11.029","volume":"117","author":"M Blaganje","year":"2012","unstructured":"Blaganje M, Lukanovic A. Intrasphincteric autologous myoblast injections with electrical stimulation for stress urinary incontinence. Int J Gynaecol Obstet. 2012;117(2):164\u20137.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"5514_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.juro.2012.09.028","volume":"189","author":"LK Carr","year":"2013","unstructured":"Carr LK, Robert M, Kultgen PL, et al. Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol. 2013;189(2):595\u2013601.","journal-title":"J Urol"},{"issue":"12","key":"5514_CR16","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s11255-018-2005-8","volume":"50","author":"RJ Jankowski","year":"2018","unstructured":"Jankowski RJ, Tu LM, Carlson C, et al. A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. Int Urol Nephrol. 2018;50(12):2153\u201365.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"5514_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/nau.22436","volume":"33","author":"J Krhut","year":"2014","unstructured":"Krhut J, Zachoval R, Smith PP, et al. Pad weight testing in the evaluation of urinary incontinence. Neurourol Urodyn. 2014;33(5):507\u201310.","journal-title":"Neurourol Urodyn"},{"key":"5514_CR18","unstructured":"R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing V, Austria. URL https:\/\/www.R-project.org\/."},{"issue":"3","key":"5514_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/(SICI)1520-6777(2000)19:3<279::AID-NAU9>3.0.CO;2-M","volume":"19","author":"MB Chancellor","year":"2000","unstructured":"Chancellor MB, Yokoyama T, Tirney S, et al. Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. Neurourol Urodyn. 2000;19(3):279\u201387.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"5514_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/nau.20448","volume":"26","author":"A Furuta","year":"2007","unstructured":"Furuta A, Jankowski RJ, Honda M, Pruchnic R, Yoshimura N, Chancellor MB. State of the art of where we are at using stem cells for stress urinary incontinence. Neurourol Urodyn. 2007;26(7):966\u201371.","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"5514_CR21","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3727\/096368911X623835","volume":"21","author":"D Eberli","year":"2012","unstructured":"Eberli D, Aboushwareb T, Soker S, Yoo JJ, Atala A. Muscle precursor cells for the restoration of irreversibly damaged sphincter function. Cell Transplant. 2012;21(9):2089\u201398.","journal-title":"Cell Transplant"},{"issue":"5","key":"5514_CR22","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.juro.2013.04.052","volume":"190","author":"S Badra","year":"2013","unstructured":"Badra S, Andersson KE, Dean A, Mourad S, Williams JK. Long-term structural and functional effects of autologous muscle precursor cell therapy in a nonhuman primate model of urinary sphincter deficiency. J Urol. 2013;190(5):1938\u201345.","journal-title":"J Urol"},{"issue":"2","key":"5514_CR23","doi-asserted-by":"publisher","first-page":"e1108","DOI":"10.1002\/term.2444","volume":"12","author":"A Vinarov","year":"2018","unstructured":"Vinarov A, Atala A, Yoo J, et al. Cell therapy for stress urinary incontinence: present-day frontiers. J Tissue Eng Regen Med. 2018;12(2):e1108\u201321.","journal-title":"J Tissue Eng Regen Med"},{"issue":"7","key":"5514_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1464-410X.2012.11682.x","volume":"111","author":"R Yiou","year":"2013","unstructured":"Yiou R, Hogrel JY, Loche CM, et al. Periurethral skeletal myofibre implantation in patients with urinary incontinence and intrinsic sphincter deficiency: a phase I clinical trial. BJU Int. 2013;111(7):1105\u201316.","journal-title":"BJU Int"},{"issue":"3","key":"5514_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2014.04.005","volume":"192","author":"S Gras","year":"2014","unstructured":"Gras S, Klarskov N, Lose G. Intraurethral injection of autologous minced skeletal muscle: a simple surgical treatment for stress urinary incontinence. J Urol. 2014;192(3):850\u20135.","journal-title":"J Urol"},{"key":"5514_CR26","doi-asserted-by":"crossref","unstructured":"Schmid FA, Williams JK, Kessler TM, et al. Treatment of stress urinary incontinence with muscle stem cells and stem cell components: chances, challenges and future prospects. Int J Mol Sci. 2021;22(8):3981.","DOI":"10.3390\/ijms22083981"},{"issue":"2","key":"5514_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.juro.2014.02.047","volume":"192","author":"KM Peters","year":"2014","unstructured":"Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192(2):469\u201376.","journal-title":"J Urol"},{"issue":"2","key":"5514_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00192-010-1255-5","volume":"22","author":"P Sebe","year":"2011","unstructured":"Sebe P, Doucet C, Cornu JN, et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study. Int Urogynecol J. 2011;22(2):183\u20139.","journal-title":"Int Urogynecol J"},{"issue":"7","key":"5514_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/iju.13097","volume":"23","author":"F Sharifiaghdas","year":"2016","unstructured":"Sharifiaghdas F, Tajalli F, Taheri M, et al. Effect of autologous muscle-derived cells in the treatment of urinary incontinence in female patients with intrinsic sphincter deficiency and epispadias: a prospective study. Int J Urol. 2016;23(7):581\u20136.","journal-title":"Int J Urol"},{"issue":"3","key":"5514_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/nau.22404","volume":"33","author":"K Stangel-Wojcikiewicz","year":"2014","unstructured":"Stangel-Wojcikiewicz K, Jarocha D, Piwowar M, et al. Autologous muscle-derived cells for the treatment of female stress urinary incontinence: a 2-year follow-up of a Polish investigation. Neurourol Urodyn. 2014;33(3):324\u201330.","journal-title":"Neurourol Urodyn"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-023-05514-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T14:03:46Z","timestamp":1695045826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-023-05514-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["5514"],"URL":"https:\/\/doi.org\/10.1007\/s00192-023-05514-4","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.A.S., M.K., C.B., R.A.S., N.S., M.H., F.L., M.V., R.G., A.L., A.M.H., A.B.: none. The author(s) declared the following potential conflicts of interest with respect to the research, authorship and\/or publication of this article: J.A.P., D.M.H. and D.E. own stocks in the company MUVON Therapeutics AG, aimed at further developing MPC therapy towards a commercial product. No company employees were involved in conducting the study or analysis of the presented study. Besides that, no other relation, benefit, potential conflict must be reported in the context of this study. All other authors declare that the research presented in this study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}